<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231129031136&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231129031136&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Wed, 29 Nov 2023 08:11:39 +0000</lastbuilddate>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Self-monitoring strategy reduces postpartum hypertension and cardiac remodelling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38017232/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 28. doi: 10.1038/s41569-023-00966-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38017232/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38017232</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00966-z>10.1038/s41569-023-00966-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38017232</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Self-monitoring strategy reduces postpartum hypertension and cardiac remodelling</dc:title>
<dc:identifier>pmid:38017232</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00966-z</dc:identifier>
</item>
<item>
<title>Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38016470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>Most animals require sleep, and sleep loss induces serious pathophysiological consequences, including death. Previous experimental approaches for investigating sleep impacts in mice have been unable to persistently deprive animals of both rapid eye movement sleep (REMS) and non-rapid eye movement sleep (NREMS). Here, we report a "curling prevention by water" paradigm wherein mice remain awake 96% of the time. After 4 days of exposure, mice exhibit severe inflammation, and approximately 80% die....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 14:S0092-8674(23)01176-5. doi: 10.1016/j.cell.2023.10.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Most animals require sleep, and sleep loss induces serious pathophysiological consequences, including death. Previous experimental approaches for investigating sleep impacts in mice have been unable to persistently deprive animals of both rapid eye movement sleep (REMS) and non-rapid eye movement sleep (NREMS). Here, we report a "curling prevention by water" paradigm wherein mice remain awake 96% of the time. After 4 days of exposure, mice exhibit severe inflammation, and approximately 80% die. Sleep deprivation increases levels of prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) in the brain, and we found that elevated PGD<sub>2</sub> efflux across the blood-brain-barrier-mediated by ATP-binding cassette subfamily C4 transporter-induces both accumulation of circulating neutrophils and a cytokine-storm-like syndrome. Experimental disruption of the PGD<sub>2</sub>/DP1 axis dramatically reduced sleep-deprivation-induced inflammation. Thus, our study reveals that sleep-related changes in PGD<sub>2</sub> in the central nervous system drive profound pathological consequences in the peripheral immune system.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38016470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38016470</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.025>10.1016/j.cell.2023.10.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38016470</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Di Sang</dc:creator>
<dc:creator>Keteng Lin</dc:creator>
<dc:creator>Yini Yang</dc:creator>
<dc:creator>Guangdi Ran</dc:creator>
<dc:creator>Bohan Li</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:creator>Qi Li</dc:creator>
<dc:creator>Yan Ma</dc:creator>
<dc:creator>Lihui Lu</dc:creator>
<dc:creator>Xi-Yang Cui</dc:creator>
<dc:creator>Zhibo Liu</dc:creator>
<dc:creator>Sheng-Qing Lv</dc:creator>
<dc:creator>Minmin Luo</dc:creator>
<dc:creator>Qinghua Liu</dc:creator>
<dc:creator>Yulong Li</dc:creator>
<dc:creator>Eric Erquan Zhang</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals</dc:title>
<dc:identifier>pmid:38016470</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.025</dc:identifier>
</item>
<item>
<title>TScan-II: A genome-scale platform for the de novo identification of CD4&lt;sup>;+&lt;/sup>; T cell epitopes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38016469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>CD4^(+) T cells play fundamental roles in orchestrating immune responses and tissue homeostasis. However, our inability to associate peptide human leukocyte antigen class-II (HLA-II) complexes with their cognate T cell receptors (TCRs) in an unbiased manner has hampered our understanding of CD4^(+) T cell function and role in pathologies. Here, we introduce TScan-II, a highly sensitive genome-scale CD4^(+) antigen discovery platform. This platform seamlessly integrates the endogenous HLA-II...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 16:S0092-8674(23)01175-3. doi: 10.1016/j.cell.2023.10.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CD4<sup>+</sup> T cells play fundamental roles in orchestrating immune responses and tissue homeostasis. However, our inability to associate peptide human leukocyte antigen class-II (HLA-II) complexes with their cognate T cell receptors (TCRs) in an unbiased manner has hampered our understanding of CD4<sup>+</sup> T cell function and role in pathologies. Here, we introduce TScan-II, a highly sensitive genome-scale CD4<sup>+</sup> antigen discovery platform. This platform seamlessly integrates the endogenous HLA-II antigen-processing machinery in synthetic antigen-presenting cells and TCR signaling in T cells, enabling the simultaneous screening of multiple HLAs and TCRs. Leveraging genome-scale human, virome, and epitope mutagenesis libraries, TScan-II facilitates de novo antigen discovery and deep exploration of TCR specificity. We demonstrate TScan-II's potential for basic and translational research by identifying a non-canonical antigen for a cancer-reactive CD4<sup>+</sup> T cell clone. Additionally, we identified two antigens for clonally expanded CD4<sup>+</sup> T cells in Sjögren's disease, which bind distinct HLAs and are expressed in HLA-II-positive ductal cells within affected salivary glands.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38016469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38016469</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.024>10.1016/j.cell.2023.10.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38016469</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Mohammad H Dezfulian</dc:creator>
<dc:creator>Tomasz Kula</dc:creator>
<dc:creator>Thomas Pranzatelli</dc:creator>
<dc:creator>Nolan Kamitaki</dc:creator>
<dc:creator>Qingda Meng</dc:creator>
<dc:creator>Bhuwan Khatri</dc:creator>
<dc:creator>Paola Perez</dc:creator>
<dc:creator>Qikai Xu</dc:creator>
<dc:creator>Aiquan Chang</dc:creator>
<dc:creator>Ayano C Kohlgruber</dc:creator>
<dc:creator>Yumei Leng</dc:creator>
<dc:creator>Ananth Aditya Jupudi</dc:creator>
<dc:creator>Michelle L Joachims</dc:creator>
<dc:creator>John A Chiorini</dc:creator>
<dc:creator>Christopher J Lessard</dc:creator>
<dc:creator>A Darise Farris</dc:creator>
<dc:creator>Senthil K Muthuswamy</dc:creator>
<dc:creator>Blake M Warner</dc:creator>
<dc:creator>Stephen J Elledge</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>TScan-II: A genome-scale platform for the de novo identification of CD4&lt;sup>;+&lt;/sup>; T cell epitopes</dc:title>
<dc:identifier>pmid:38016469</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.024</dc:identifier>
</item>
<item>
<title>Optical coherence tomography to guide percutaneous coronary intervention: is the glass half full or half empty?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38015998/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 28:ehad792. doi: 10.1093/eurheartj/ehad792. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38015998/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38015998</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad792>10.1093/eurheartj/ehad792</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38015998</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Optical coherence tomography to guide percutaneous coronary intervention: is the glass half full or half empty?</dc:title>
<dc:identifier>pmid:38015998</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad792</dc:identifier>
</item>
<item>
<title>Atrial fibrillation first detected after stroke: is timing and detection intensity relevant for stroke risk?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38014646/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 28:ehad744. doi: 10.1093/eurheartj/ehad744. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38014646/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38014646</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad744>10.1093/eurheartj/ehad744</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38014646</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Luciano A Sposato</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Karl Georg Haeusler</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation first detected after stroke: is timing and detection intensity relevant for stroke risk?</dc:title>
<dc:identifier>pmid:38014646</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad744</dc:identifier>
</item>
<item>
<title>Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38014550/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Childhood non-HDL-C and LDL-C levels are associated with ASCVD events in midlife. Non-HDL-C is better than LDL-C in predicting adult ASCVD events, particularly among individuals who had normal LDL-C but elevated non-HDL-C. These findings suggest that both non-HDL-C and LDL-C are useful in identifying children at higher risk of ASCVD events, but non-HDL-C may provide added prognostic information when it is discordantly higher than the corresponding LDL-C and has the practical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28. doi: 10.1161/CIRCULATIONAHA.123.064296. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although low-density lipoprotein cholesterol (LDL-C) remains the primary cholesterol target in clinical practice in children and adults, non-high-density lipoprotein cholesterol (non-HDL-C) has been suggested as a more accurate measure of atherosclerotic cardiovascular disease (ASCVD) risk. We examined the associations of childhood non-HDL-C and LDL-C levels with adult ASCVD events and determined whether non-HDL-C has better utility than LDL-C in predicting adult ASCVD events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This prospective cohort study included 21 126 participants from the i3C Consortium (International Childhood Cardiovascular Cohorts). Proportional hazards regressions were used to estimate the risk for incident fatal and fatal/nonfatal ASCVD events associated with childhood non-HDL-C and LDL-C levels (age- and sex-specific <i>z</i> scores; concordant/discordant categories defined by guideline-recommended cutoffs), adjusted for sex, Black race, cohort, age at and calendar year of child measurement, body mass index, and systolic blood pressure. Predictive utility was determined by the C index.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: After an average follow-up of 35 years, 153 fatal ASCVD events occurred in 21 126 participants (mean age at childhood visits, 11.9 years), and 352 fatal/nonfatal ASCVD events occurred in a subset of 11 296 participants who could be evaluated for this outcome. Childhood non-HDL-C and LDL-C levels were each associated with higher risk of fatal and fatal/nonfatal ASCVD events (hazard ratio ranged from 1.27 [95% CI, 1.14-1.41] to 1.35 [95% CI, 1.13-1.60] per unit increase in the risk factor <i>z</i> score). Non-HDL-C had better discriminative utility than LDL-C (difference in C index, 0.0054 [95% CI, 0.0006-0.0102] and 0.0038 [95% CI, 0.0008-0.0068] for fatal and fatal/nonfatal events, respectively). The discordant group with elevated non-HDL-C and normal LDL-C had a higher risk of ASCVD events compared with the concordant group with normal non-HDL-C and LDL-C (fatal events: hazard ratio, 1.90 [95% CI, 0.98-3.70]; fatal/nonfatal events: hazard ratio, 1.94 [95% CI, 1.23-3.06]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Childhood non-HDL-C and LDL-C levels are associated with ASCVD events in midlife. Non-HDL-C is better than LDL-C in predicting adult ASCVD events, particularly among individuals who had normal LDL-C but elevated non-HDL-C. These findings suggest that both non-HDL-C and LDL-C are useful in identifying children at higher risk of ASCVD events, but non-HDL-C may provide added prognostic information when it is discordantly higher than the corresponding LDL-C and has the practical advantage of being determined without a fasting sample.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38014550/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38014550</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064296>10.1161/CIRCULATIONAHA.123.064296</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38014550</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Feitong Wu</dc:creator>
<dc:creator>Markus Juonala</dc:creator>
<dc:creator>David R Jacobs</dc:creator>
<dc:creator>Stephen R Daniels</dc:creator>
<dc:creator>Mika Kähönen</dc:creator>
<dc:creator>Jessica G Woo</dc:creator>
<dc:creator>Alan R Sinaiko</dc:creator>
<dc:creator>Jorma S A Viikari</dc:creator>
<dc:creator>Lydia A Bazzano</dc:creator>
<dc:creator>Trudy L Burns</dc:creator>
<dc:creator>Julia Steinberger</dc:creator>
<dc:creator>Elaine M Urbina</dc:creator>
<dc:creator>Alison J Venn</dc:creator>
<dc:creator>Olli T Raitakari</dc:creator>
<dc:creator>Terence Dwyer</dc:creator>
<dc:creator>Costan G Magnussen</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events</dc:title>
<dc:identifier>pmid:38014550</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064296</dc:identifier>
</item>
<item>
<title>Critical Care Management of Patients After Cardiac Arrest: A Scientific Statement From the American Heart Association and Neurocritical Care Society</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38014539/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>The critical care management of patients after cardiac arrest is burdened by a lack of high-quality clinical studies and the resultant lack of high-certainty evidence. This results in limited practice guideline recommendations, which may lead to uncertainty and variability in management. Critical care management is crucial in patients after cardiac arrest and affects outcome. Although guidelines address some relevant topics (including temperature control and neurological prognostication of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28. doi: 10.1161/CIR.0000000000001163. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The critical care management of patients after cardiac arrest is burdened by a lack of high-quality clinical studies and the resultant lack of high-certainty evidence. This results in limited practice guideline recommendations, which may lead to uncertainty and variability in management. Critical care management is crucial in patients after cardiac arrest and affects outcome. Although guidelines address some relevant topics (including temperature control and neurological prognostication of comatose survivors, 2 topics for which there are more robust clinical studies), many important subject areas have limited or nonexistent clinical studies, leading to the absence of guidelines or low-certainty evidence. The American Heart Association Emergency Cardiovascular Care Committee and the Neurocritical Care Society collaborated to address this gap by organizing an expert consensus panel and conference. Twenty-four experienced practitioners (including physicians, nurses, pharmacists, and a respiratory therapist) from multiple medical specialties, levels, institutions, and countries made up the panel. Topics were identified and prioritized by the panel and arranged by organ system to facilitate discussion, debate, and consensus building. Statements related to postarrest management were generated, and 80% agreement was required to approve a statement. Voting was anonymous and web based. Topics addressed include neurological, cardiac, pulmonary, hematological, infectious, gastrointestinal, endocrine, and general critical care management. Areas of uncertainty, areas for which no consensus was reached, and future research directions are also included. Until high-quality studies that inform practice guidelines in these areas are available, the expert panel consensus statements that are provided can advise clinicians on the critical care management of patients after cardiac arrest.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38014539/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38014539</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001163>10.1161/CIR.0000000000001163</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38014539</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Karen G Hirsch</dc:creator>
<dc:creator>Benjamin S Abella</dc:creator>
<dc:creator>Edilberto Amorim</dc:creator>
<dc:creator>Mary Kay Bader</dc:creator>
<dc:creator>Jeffrey F Barletta</dc:creator>
<dc:creator>Katherine Berg</dc:creator>
<dc:creator>Clifton W Callaway</dc:creator>
<dc:creator>Hans Friberg</dc:creator>
<dc:creator>Emily J Gilmore</dc:creator>
<dc:creator>David M Greer</dc:creator>
<dc:creator>Karl B Kern</dc:creator>
<dc:creator>Sarah Livesay</dc:creator>
<dc:creator>Teresa L May</dc:creator>
<dc:creator>Robert W Neumar</dc:creator>
<dc:creator>Jerry P Nolan</dc:creator>
<dc:creator>Mauro Oddo</dc:creator>
<dc:creator>Mary Ann Peberdy</dc:creator>
<dc:creator>Samuel M Poloyac</dc:creator>
<dc:creator>David Seder</dc:creator>
<dc:creator>Fabio Silvio Taccone</dc:creator>
<dc:creator>Anezi Uzendu</dc:creator>
<dc:creator>Brian Walsh</dc:creator>
<dc:creator>Janice L Zimmerman</dc:creator>
<dc:creator>Romergryko G Geocadin</dc:creator>
<dc:creator>American Heart Association and Neurocritical Care Society</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Critical Care Management of Patients After Cardiac Arrest: A Scientific Statement From the American Heart Association and Neurocritical Care Society</dc:title>
<dc:identifier>pmid:38014539</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001163</dc:identifier>
</item>
<item>
<title>Aspirin exclusion in patients with an LVAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38012304/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 27. doi: 10.1038/s41569-023-00965-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38012304/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38012304</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00965-0>10.1038/s41569-023-00965-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38012304</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Aspirin exclusion in patients with an LVAD</dc:title>
<dc:identifier>pmid:38012304</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00965-0</dc:identifier>
</item>
<item>
<title>Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1746-1749. doi: 10.1161/CIRCULATIONAHA.123.066915. Epub 2023 Nov 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38011247</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066915>10.1161/CIRCULATIONAHA.123.066915</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011247</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics</dc:title>
<dc:identifier>pmid:38011247</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066915</dc:identifier>
</item>
<item>
<title>Making the Right Diagnosis: Slowly but Surely</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1814-1818. doi: 10.1161/CIRCULATIONAHA.123.067074. Epub 2023 Nov 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38011246</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10664777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">PMC10664777</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067074>10.1161/CIRCULATIONAHA.123.067074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011246</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Parag R Gajendragadkar</dc:creator>
<dc:creator>Claire A Martin</dc:creator>
<dc:creator>Rohan S Wijesurendra</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Making the Right Diagnosis: Slowly but Surely</dc:title>
<dc:identifier>pmid:38011246</dc:identifier>
<dc:identifier>pmc:PMC10664777</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067074</dc:identifier>
</item>
<item>
<title>Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) with clinical and subclinical episodes occurring in nearly one-half of patients. AF in HCM historically has been characterized as a decisive disease complication associated with substantial risk for thromboembolic stroke and increased morbidity and mortality. However, there have been many advances in treatment strategy resulting in improved outcomes for this patient group. For example, stroke...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1797-1811. doi: 10.1161/CIRCULATIONAHA.123.065037. Epub 2023 Nov 27.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) with clinical and subclinical episodes occurring in nearly one-half of patients. AF in HCM historically has been characterized as a decisive disease complication associated with substantial risk for thromboembolic stroke and increased morbidity and mortality. However, there have been many advances in treatment strategy resulting in improved outcomes for this patient group. For example, stroke risk in HCM has been greatly reduced by using systemic oral anticoagulation initiated after the first clinical (symptomatic) AF episode, usually with preference given to direct anticoagulants over warfarin. In contrast, stroke risk scoring systems (such as CHA<sub>2</sub>DS<sub>2</sub>-VASc score) are not informative in HCM given the substantial potential for stroke events in patients with low scores, and therefore should not be used for anticoagulation decisions in this disease. A novel risk score specifically designed for HCM (HCM-AF score) can reliably identify most patients with HCM at risk for future AF. Although a strategy focused on controlling ventricular rate is effective in asymptomatic (or minimally symptomatic) patients with AF, restoring and maintaining sinus rhythm is required for most patients with marked AF symptom burden and impaired quality of life. Several antiarrhythmic drugs such as sotalol, disopyramide, and amiodarone, can be effective in suppressing AF episodes; albeit safe, long-term efficacy is supported by only limited data. Catheter AF ablation has emerged as an important treatment option for some patients, although freedom from AF after a single ablation is relatively low (35% at 3 years), multiple ablations and the concomitant use of antiarrhythmic drugs can control AF with more than two-thirds of patients maintaining sinus rhythm at 5 years. Surgical AF ablation with biatrial Cox-Maze IV performed as an adjunctive procedure during myectomy can reduce symptomatic AF episodes (70% of patients free from AF at 5 years). For the vast majority of patients who have HCM with AF, the implementation of contemporary therapies has allowed for improved quality of life and low HCM-related mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38011245</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065037>10.1161/CIRCULATIONAHA.123.065037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011245</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ethan J Rowin</dc:creator>
<dc:creator>Mark S Link</dc:creator>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Barry J Maron</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38011245</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065037</dc:identifier>
</item>
<item>
<title>Epitranscriptomic Modification of MicroRNA Increases Atherosclerosis Susceptibility</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1819-1822. doi: 10.1161/CIRCULATIONAHA.123.065455. Epub 2023 Nov 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38011244</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10683863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">PMC10683863</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065455>10.1161/CIRCULATIONAHA.123.065455</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011244</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ming He</dc:creator>
<dc:creator>Jianjie Dong</dc:creator>
<dc:creator>Junmao Wen</dc:creator>
<dc:creator>Yuqing Zhang</dc:creator>
<dc:creator>So Yun Han</dc:creator>
<dc:creator>Chen Wang</dc:creator>
<dc:creator>Brendan Gongol</dc:creator>
<dc:creator>Tong-You Wade Wei</dc:creator>
<dc:creator>Jian Kang</dc:creator>
<dc:creator>Hsi-Yuan Huang</dc:creator>
<dc:creator>Susan Cheng</dc:creator>
<dc:creator>John Y-J Shyy</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Epitranscriptomic Modification of MicroRNA Increases Atherosclerosis Susceptibility</dc:title>
<dc:identifier>pmid:38011244</dc:identifier>
<dc:identifier>pmc:PMC10683863</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065455</dc:identifier>
</item>
<item>
<title>Response by Walters et al to Letter Regarding Article, "&lt;em>;SOX17&lt;/em>; Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1825-1826. doi: 10.1161/CIRCULATIONAHA.123.066621. Epub 2023 Nov 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38011243</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066621>10.1161/CIRCULATIONAHA.123.066621</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011243</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Rachel Walters</dc:creator>
<dc:creator>Eleni Vasilaki</dc:creator>
<dc:creator>Martin R Wilkins</dc:creator>
<dc:creator>Lan Zhao</dc:creator>
<dc:creator>Christopher J Rhodes</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Walters et al to Letter Regarding Article, "&lt;em>;SOX17&lt;/em>; Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension"</dc:title>
<dc:identifier>pmid:38011243</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066621</dc:identifier>
</item>
<item>
<title>Groups Urge a Return to LDL-C Monitoring as a Quality Metric</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011242/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1812-1813. doi: 10.1161/CIRCULATIONAHA.123.066156. Epub 2023 Nov 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011242/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38011242</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066156>10.1161/CIRCULATIONAHA.123.066156</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011242</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Bridget M Kuehn</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Groups Urge a Return to LDL-C Monitoring as a Quality Metric</dc:title>
<dc:identifier>pmid:38011242</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066156</dc:identifier>
</item>
<item>
<title>Letter by Li et al Regarding Article, "&lt;em>;SOX17&lt;/em>; Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011241/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1823-1824. doi: 10.1161/CIRCULATIONAHA.123.066230. Epub 2023 Nov 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011241/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38011241</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066230>10.1161/CIRCULATIONAHA.123.066230</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011241</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Guling Li</dc:creator>
<dc:creator>Hui Chen</dc:creator>
<dc:creator>Chuanli Ren</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Li et al Regarding Article, "&lt;em>;SOX17&lt;/em>; Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension"</dc:title>
<dc:identifier>pmid:38011241</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066230</dc:identifier>
</item>
<item>
<title>Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38001231/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>Despite prompt epicardial recanalization in patients presenting with ST-segment elevation myocardial infarction (STEMI), coronary microvascular obstruction and dysfunction (CMVO) is still fairly common and is associated with poor prognosis. Various pharmacological and mechanical strategies to treat CMVO have been proposed, but the positive results reported in preclinical and small proof-of-concept studies have not translated into benefits in large clinical trials conducted in the modern...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 24. doi: 10.1038/s41569-023-00953-4. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite prompt epicardial recanalization in patients presenting with ST-segment elevation myocardial infarction (STEMI), coronary microvascular obstruction and dysfunction (CMVO) is still fairly common and is associated with poor prognosis. Various pharmacological and mechanical strategies to treat CMVO have been proposed, but the positive results reported in preclinical and small proof-of-concept studies have not translated into benefits in large clinical trials conducted in the modern treatment setting of patients with STEMI. Therefore, the optimal management of these patients remains a topic of debate. In this Review, we appraise the pathophysiological mechanisms of CMVO, explore the evidence and provide future perspectives on strategies to be implemented to reduce the incidence of CMVO and improve prognosis in patients with STEMI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38001231/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">38001231</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00953-4>10.1038/s41569-023-00953-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38001231</guid>
<pubDate>Fri, 24 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Mattia Galli</dc:creator>
<dc:creator>Giampaolo Niccoli</dc:creator>
<dc:creator>Gianluigi De Maria</dc:creator>
<dc:creator>Salvatore Brugaletta</dc:creator>
<dc:creator>Rocco A Montone</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Stefano Benenati</dc:creator>
<dc:creator>Giulia Magniani</dc:creator>
<dc:creator>Domenico D'Amario</dc:creator>
<dc:creator>Italo Porto</dc:creator>
<dc:creator>Francesco Burzotta</dc:creator>
<dc:creator>Antonio Abbate</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-11-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction</dc:title>
<dc:identifier>pmid:38001231</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00953-4</dc:identifier>
</item>
<item>
<title>On target inhibition of vascular smooth muscle cell phenotypic transition underpins TNF-OXPHOS-AP-1 as a promising avenue for anti-remodelling interventions in aortic dissection and rupture</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37997934/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 24:ehad679. doi: 10.1093/eurheartj/ehad679. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37997934/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">37997934</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad679>10.1093/eurheartj/ehad679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37997934</guid>
<pubDate>Fri, 24 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kapka Miteva</dc:creator>
<dc:date>2023-11-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>On target inhibition of vascular smooth muscle cell phenotypic transition underpins TNF-OXPHOS-AP-1 as a promising avenue for anti-remodelling interventions in aortic dissection and rupture</dc:title>
<dc:identifier>pmid:37997934</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad679</dc:identifier>
</item>
<item>
<title>Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995658/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 22;186(24):5428-5432. doi: 10.1016/j.cell.2023.10.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995658/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">37995658</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.008>10.1016/j.cell.2023.10.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995658</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Man Lung Yeung</dc:creator>
<dc:creator>Jade Lee Lee Teng</dc:creator>
<dc:creator>Lilong Jia</dc:creator>
<dc:creator>Chaoyu Zhang</dc:creator>
<dc:creator>Chengxi Huang</dc:creator>
<dc:creator>Jian-Piao Cai</dc:creator>
<dc:creator>Runhong Zhou</dc:creator>
<dc:creator>Kwok-Hung Chan</dc:creator>
<dc:creator>Hanjun Zhao</dc:creator>
<dc:creator>Lin Zhu</dc:creator>
<dc:creator>Kam-Leung Siu</dc:creator>
<dc:creator>Sin-Yee Fung</dc:creator>
<dc:creator>Susan Yung</dc:creator>
<dc:creator>Tak Mao Chan</dc:creator>
<dc:creator>Kelvin Kai-Wang To</dc:creator>
<dc:creator>Jasper Fuk-Woo Chan</dc:creator>
<dc:creator>Zongwei Cai</dc:creator>
<dc:creator>Susanna Kar Pui Lau</dc:creator>
<dc:creator>Zhiwei Chen</dc:creator>
<dc:creator>Dong-Yan Jin</dc:creator>
<dc:creator>Patrick Chiu Yat Woo</dc:creator>
<dc:creator>Kwok-Yung Yuen</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system</dc:title>
<dc:identifier>pmid:37995658</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.008</dc:identifier>
</item>
<item>
<title>S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>Itch is an unpleasant sensation that evokes a desire to scratch. The skin barrier is constantly exposed to microbes and their products. However, the role of microbes in itch generation is unknown. Here, we show that Staphylococcus aureus, a bacterial pathogen associated with itchy skin diseases, directly activates pruriceptor sensory neurons to drive itch. Epicutaneous S. aureus exposure causes robust itch and scratch-induced damage. By testing multiple isogenic bacterial mutants for virulence...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 22;186(24):5375-5393.e25. doi: 10.1016/j.cell.2023.10.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Itch is an unpleasant sensation that evokes a desire to scratch. The skin barrier is constantly exposed to microbes and their products. However, the role of microbes in itch generation is unknown. Here, we show that Staphylococcus aureus, a bacterial pathogen associated with itchy skin diseases, directly activates pruriceptor sensory neurons to drive itch. Epicutaneous S. aureus exposure causes robust itch and scratch-induced damage. By testing multiple isogenic bacterial mutants for virulence factors, we identify the S. aureus serine protease V8 as a critical mediator in evoking spontaneous itch and alloknesis. V8 cleaves proteinase-activated receptor 1 (PAR1) on mouse and human sensory neurons. Targeting PAR1 through genetic deficiency, small interfering RNA (siRNA) knockdown, or pharmacological blockade decreases itch and skin damage caused by V8 and S. aureus exposure. Thus, we identify a mechanism of action for a pruritogenic bacterial factor and demonstrate the potential of inhibiting V8-PAR1 signaling to treat itch.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">37995657</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10669764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">PMC10669764</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.019>10.1016/j.cell.2023.10.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995657</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Liwen Deng</dc:creator>
<dc:creator>Flavia Costa</dc:creator>
<dc:creator>Kimbria J Blake</dc:creator>
<dc:creator>Samantha Choi</dc:creator>
<dc:creator>Arundhasa Chandrabalan</dc:creator>
<dc:creator>Muhammad Saad Yousuf</dc:creator>
<dc:creator>Stephanie Shiers</dc:creator>
<dc:creator>Daniel Dubreuil</dc:creator>
<dc:creator>Daniela Vega-Mendoza</dc:creator>
<dc:creator>Corinne Rolland</dc:creator>
<dc:creator>Celine Deraison</dc:creator>
<dc:creator>Tiphaine Voisin</dc:creator>
<dc:creator>Michelle D Bagood</dc:creator>
<dc:creator>Lucia Wesemann</dc:creator>
<dc:creator>Abigail M Frey</dc:creator>
<dc:creator>Joseph S Palumbo</dc:creator>
<dc:creator>Brian J Wainger</dc:creator>
<dc:creator>Richard L Gallo</dc:creator>
<dc:creator>Juan-Manuel Leyva-Castillo</dc:creator>
<dc:creator>Nathalie Vergnolle</dc:creator>
<dc:creator>Theodore J Price</dc:creator>
<dc:creator>Rithwik Ramachandran</dc:creator>
<dc:creator>Alexander R Horswill</dc:creator>
<dc:creator>Isaac M Chiu</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis</dc:title>
<dc:identifier>pmid:37995657</dc:identifier>
<dc:identifier>pmc:PMC10669764</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.019</dc:identifier>
</item>
<item>
<title>Lineage-specific 3D genome organization is assembled at multiple scales by IKAROS</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995656/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>A generic level of chromatin organization generated by the interplay between cohesin and CTCF suffices to limit promiscuous interactions between regulatory elements, but a lineage-specific chromatin assembly that supersedes these constraints is required to configure the genome to guide gene expression changes that drive faithful lineage progression. Loss-of-function approaches in B cell precursors show that IKAROS assembles interactions across megabase distances in preparation for lymphoid...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 22;186(24):5269-5289.e22. doi: 10.1016/j.cell.2023.10.023.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A generic level of chromatin organization generated by the interplay between cohesin and CTCF suffices to limit promiscuous interactions between regulatory elements, but a lineage-specific chromatin assembly that supersedes these constraints is required to configure the genome to guide gene expression changes that drive faithful lineage progression. Loss-of-function approaches in B cell precursors show that IKAROS assembles interactions across megabase distances in preparation for lymphoid development. Interactions emanating from IKAROS-bound enhancers override CTCF-imposed boundaries to assemble lineage-specific regulatory units built on a backbone of smaller invariant topological domains. Gain of function in epithelial cells confirms IKAROS' ability to reconfigure chromatin architecture at multiple scales. Although the compaction of the Igκ locus required for genome editing represents a function of IKAROS unique to lymphocytes, the more general function to preconfigure the genome to support lineage-specific gene expression and suppress activation of extra-lineage genes provides a paradigm for lineage restriction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995656/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">37995656</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.023>10.1016/j.cell.2023.10.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995656</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Yeguang Hu</dc:creator>
<dc:creator>Daniela Salgado Figueroa</dc:creator>
<dc:creator>Zhihong Zhang</dc:creator>
<dc:creator>Margaret Veselits</dc:creator>
<dc:creator>Sourya Bhattacharyya</dc:creator>
<dc:creator>Mariko Kashiwagi</dc:creator>
<dc:creator>Marcus R Clark</dc:creator>
<dc:creator>Bruce A Morgan</dc:creator>
<dc:creator>Ferhat Ay</dc:creator>
<dc:creator>Katia Georgopoulos</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Lineage-specific 3D genome organization is assembled at multiple scales by IKAROS</dc:title>
<dc:identifier>pmid:37995656</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.023</dc:identifier>
</item>
<item>
<title>Molecular basis of opioid receptor signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995655/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129031136&amp;v=2.17.9.post6+86293ac
      <description>Opioids are used for pain management despite the side effects that contribute to the opioid crisis. The pursuit of non-addictive opioid analgesics remains unattained due to the unresolved intricacies of opioid actions, receptor signaling cascades, and neuronal plasticity. Advancements in structural, molecular, and computational tools illuminate the dynamic interplay between opioids and opioid receptors, as well as the molecular determinants of signaling pathways, which are potentially...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 22;186(24):5203-5219. doi: 10.1016/j.cell.2023.10.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Opioids are used for pain management despite the side effects that contribute to the opioid crisis. The pursuit of non-addictive opioid analgesics remains unattained due to the unresolved intricacies of opioid actions, receptor signaling cascades, and neuronal plasticity. Advancements in structural, molecular, and computational tools illuminate the dynamic interplay between opioids and opioid receptors, as well as the molecular determinants of signaling pathways, which are potentially interlinked with pharmacological responses. Here, we review the molecular basis of opioid receptor signaling with a focus on the structures of opioid receptors bound to endogenous peptides or pharmacological agents. These insights unveil specific interactions that dictate ligand selectivity and likely their distinctive pharmacological profiles. Biochemical analysis further unveils molecular features governing opioid receptor signaling. Simultaneously, the synergy between computational biology and medicinal chemistry continues to expedite the discovery of novel chemotypes with the promise of yielding more efficacious and safer opioid compounds.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995655/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129031136&v=2.17.9.post6+86293ac">37995655</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.029>10.1016/j.cell.2023.10.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995655</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Tao Che</dc:creator>
<dc:creator>Bryan L Roth</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Molecular basis of opioid receptor signaling</dc:title>
<dc:identifier>pmid:37995655</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.029</dc:identifier>
</item>





























</channel>
</rss>